The HIF pathway as a therapeutic target
- PMID: 15341784
- DOI: 10.1016/S1359-6446(04)03202-7
The HIF pathway as a therapeutic target
Abstract
Hypoxia-inducible factor (HIF) is an alpha,beta-heterodimeric transcription factor that mediates cellular responses to low oxygen concentration via the transcriptional activation of specific genes involved in both tumorogenesis and angiogenesis. Manipulation of the HIF pathway has potential use for the treatment of ischemic disease and cancer. Unlike HIF-beta, which is constitutively expressed, the levels and activity of the HIF-alpha subunit are regulated by processes involving posttranslational hydroxylation, catalyzed by Fe(II)- and 2-oxoglutarate-dependent oxygenases. This review focuses on the HIF pathway as a therapeutic target.
Comment in
-
Drug discovery in the HIF pathway: where do we go now?Drug Discov Today. 2004 Sep 15;9(18):782-3. doi: 10.1016/S1359-6446(04)03210-6. Drug Discov Today. 2004. PMID: 15364064 No abstract available.
-
Targeting HIF-alpha: when a magic arrow hits the bull's eye.Drug Discov Today. 2004 Oct 15;9(20):869. doi: 10.1016/s1359-6446(04)03227-1. Drug Discov Today. 2004. PMID: 15493075 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
